CAJ | 학술논문

目的：评价卡培他滨联合奥沙利铂治疗晚期胃癌的有效性和安全性。方法通过数据库检索发表的相关文献，按照Jadad质量计分法对所纳入的文献进行方法学质量评估；运用Review Manager 5.0对评价卡培他滨联合奥沙利铂治疗晚期胃癌的有效性与不良反应发生率进行荟萃分析。结果纳入随机对照研究的文献共9篇。荟萃分析结果显示：治疗组有效率为55.12％，其对照组有效率为39.53％（ OR＝1.40，95％CI 1.18～1.66）。在不良反应方面，治疗组与对照组比较，引起的恶心、呕吐等胃肠反应、骨髓抑制、白细胞计数等方面的发生率明显降低，差异有统计学意义（P ＜0.05）。而对于血小板减少、口腔炎等不良反应的发生率，两组间的差异无统计学意义（ P＞0.05）。结论卡培他滨联合奥沙利铂治疗晚期胃癌化疗方案有效、安全。
목적：평개잡배타빈연합오사리박치료만기위암적유효성화안전성。방법통과수거고검색발표적상관문헌，안조Jadad질량계분법대소납입적문헌진행방법학질량평고；운용Review Manager 5.0대평개잡배타빈연합오사리박치료만기위암적유효성여불량반응발생솔진행회췌분석。결과납입수궤대조연구적문헌공9편。회췌분석결과현시：치료조유효솔위55.12％，기대조조유효솔위39.53％（ OR＝1.40，95％CI 1.18～1.66）。재불량반응방면，치료조여대조조비교，인기적악심、구토등위장반응、골수억제、백세포계수등방면적발생솔명현강저，차이유통계학의의（P ＜0.05）。이대우혈소판감소、구강염등불량반응적발생솔，량조간적차이무통계학의의（ P＞0.05）。결론잡배타빈연합오사리박치료만기위암화료방안유효、안전。
Objective To evaluate the efficacy and safety of capecitabine combined with oxaliplatin ( XELOX) for chemotherapy of metastasis gastric cancer .Methods Through relevant literature published database retrieval ,the quality of the selected trials was assessed by Jadad-scale method .Meta-analysis about the efficacy and safety of XELOX for chemotherapy of metastasis gastric cancer was performed by using Review Manager 5.0.Results Nine RCT reports were included .The overall response rate was 55.12% in the treatment group and 39.53% in the control group(OR=1.40,95% CI:1.18-1.66).For the adverse reaction evaluation , the incidence rates of gastrointestinal adverse reaction , myelosuppression , leucopeniain treatment group were less than those in control group ( P <0.05 ) .But the adverse reactions such as thrombocytopeniaand stomatitis did not exhibit any significant differences between the two groups ( P >0.05 ) .Conclusion XELOX is safe and effective for the treatment of the patients with advanced gastric cancer.